

Ocular Therapeutix to Present at the 21st Annual NewsMakers in the Biotech Industry Investment Conference on Friday, September 26

September 16, 2014

BEDFORD, Mass.--(BUSINESS WIRE)--Sep. 16, 2014-- Ocular Therapeutix (Nasdaq: OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Amar Sawhney, Ph.D., President and Chief Executive Officer, will provide an overview of the Company at the 21st Annual BioCentury Conference during a live presentation at 3:30pm ET on September 26, 2014. Dr. Sawhney and other members of the Company's management team will also be available to participate in one-on-one meetings with investors who are registered to attend the conference. The event will be held at the Millennium Broadway Hotel & Conference Center in New York. A live webcast will be accessible through Ocular's website at www.oculartherapeutix.com in the Investors section under Calendar of Events. A replay of the presentation will also be available.

About Ocular Therapeutix

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix's lead product candidates are in Phase 3 clinical development for post-surgical ocular inflammation and pain, and Phase 2 clinical development for glaucoma and allergic conjunctivitis. The Company is also evaluating sustained-release injectable anti-VEGF drug depots for back-of-the-eye diseases. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.

Source: Ocular Therapeutix, Inc.

Investors: Ocular Therapeutix, Inc. Brad Smith Chief Financial Officer bsmith@ocutx.com or Burns McClellan on behalf of Ocular Therapeutix Kimberly Minarovich, 212-213-0006 kminarovich@burnsmc.com or Media: Scott Corning Vice President of Sales and Marketing scorning@ocutx.com